DHA and EPA Antioxidant Action Against Cellular Oxidative Stress
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cellular oxidative damage, particularly in the context of aging and neurological disorders, are inadequate in effectively addressing the imbalance between reactive oxygen species production and antioxidant defenses, leading to oxidative stress and related pathologies.
Innovation Solution
The use of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA), either in free form or incorporated into triglycerides, acts as a cellular antioxidant, inhibiting ROS production, increasing antioxidant enzyme activity, and reducing lipid peroxidation, thereby providing protective effects against oxidative damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for cellular oxidative damage, then existing therapeutic approaches are maintained, but they fail to effectively address the imbalance between ROS production and antioxidant defenses
Solution Approach 1:
The patent changes the chemical parameter by introducing omega-3 fatty acids (DHA and EPA) with specific molecular structures containing multiple double bonds. These fatty acids alter the cellular redox state by modifying ROS production parameters and antioxidant enzyme activity, thereby effectively addressing oxidative stress that conventional treatments failed to resolve
Solution Approach 2:
The patent uses omega-3 fatty acids as intermediary substances that mediate between ROS production and antioxidant defenses. These fatty acids incorporate into cell membranes and act as intermediaries to modulate the activity of antioxidant enzymes (SOD, catalase, glutathione peroxidase) and reduce ROS generation, thereby resolving the imbalance without directly neutralizing ROS
2Reliability
If DHA is administered to increase tissue concentration, then antioxidant protection is enhanced, but the metabolic conversion to EPA may decrease DHA levels at cell level
Solution Approach 1:
The patent applies preliminary action by administering both DHA and EPA together in a specific ratio (preferably 2:1 to 1:1) before metabolic conversion can occur. This simultaneous administration ensures that while DHA is converted to EPA metabolically, sufficient EPA is already present to maintain overall omega-3 levels and antioxidant protection without significant loss of protective effect
Solution Approach 2:
The patent exploits the metabolic universality between DHA and EPA, both of which are omega-3 fatty acids that can perform antioxidant functions. The invention recognizes that EPA can partially substitute for DHA's antioxidant functions, allowing the body to utilize either or both fatty acids for protective effects, thereby maintaining antioxidant protection even when DHA levels fluctuate due to metabolic conversion
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DHA significantly reduces oxidative stress, enhances antioxidant defenses, and promotes cellular adaptation to oxidative challenges, offering therapeutic benefits for neurodegenerative diseases, aging, and other pathologies associated with cellular oxidative damage.
Implementation Method 1
DHA or EPA, whether in free form or incorporated into a triglyceride, acts as a cellular antioxidant, inhibiting ROS production, increasing antioxidant enzyme activity, and reducing lipid peroxidation
Data Source
AI summary
The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.